Selective targeting of human TREX1 exonuclease by small molecule inhibitors is mediated by a conformational switch
Patricia C Hernandez, Rahul Dadabhau Kardile, Ke Shi, Nicholas H Moeller, Joseph A Rollie, Daniel A Harki, Hideki Aihara · 2026
Read Selective targeting of human TREX1 exonuclease by small molecule inhibitors is mediated by a conformational switch by Patricia C Hernandez, Rahul Dadabhau Kardile, Ke Shi, Nicholas H Moeller, Joseph A Rollie, Daniel A Harki, Hideki Aihara (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13335479.txt.
Description
Patricia C Hernandez and co-authors showed how small molecules selectively block the DNA-chewing enzyme TREX1 in a 2026 structural biology study. TREX1 clears stray cytoplasmic DNA; losing it causes autoimmune disease, while blocking it in cancer cells can wake anti-tumor immunity.
X-ray crystallography revealed the inhibitors sitting in the active site, competing with the end of the DNA substrate and hydrogen-bonding to a conserved glutamate. Binding also locks a tyrosine, Tyr129, into an alternative pose that cannot grip DNA and opens a deep hydrophobic pocket that cradles part of the drug. That pocket explains why the compounds spare the close relative TREX2 and viral cousins. The structures give medicinal chemists a blueprint for selective TREX1 blockers.
Catalog record
| CREATOR | Patricia C Hernandez, Rahul Dadabhau Kardile, Ke Shi, Nicholas H Moeller, Joseph A Rollie, Daniel A Harki, Hideki Aihara |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33549 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |